Christopher Nasveschuk

- Medicinal chemist with 13 years of experience targeting oncogenic proteins (epigenetic and beyond) - Constructed and leading the Chemical Sciences Group at C4 Therapeutics, which includes Medchem, Process, DMPK and Cheminformatics & CAAD functions - Led the CDoT (Center for Development of Therapeutics) medicinal chemistry group at the Broad Institute across projects and collaborations with Bayer and Calico - Co-invented CPI-1205, an EZH2 inhibitor, currently under clinical evaluation - Part of the lead optimization team that produced CPI-0610, a BET bromodomain inhibitor, currently under clinical evaluation - EZH2 team member from HTS hit evaluation through lead optimization - Effective collaborator with Genentech, Calico, Bayer, Roche, and Biogen scientists on joint drug discovery projects - Synthetic strategy and design based on empirically developed SAR - Structure-based drug design - Integration of in vitro data into molecule design to provide good in vivo performance - Experience managing external chemists - Contributor to intellectual property protection strategy Areas of expertise: Epigenetics, Organic/Heterocyclic chemistry, Medicinal chemistry, Hit evaluation, Hit to lead, Structure-based drug design, Library design, Lead optimization, ADME/DMPK, Targeted Protein Degradation, Complex-Induced Pharmacology Bibliography (as of Sep 2021): https://www.ncbi.nlm.nih.gov/myncbi/chris.nasveschuk.1/bibliography/public/